Literature DB >> 17671423

Hypoxic suppression of the cell cycle gene CDC25A in tumor cells.

Stefanie Hammer1, Kenneth K-W To, Young-Gun Yoo, Minori Koshiji, L Eric Huang.   

Abstract

Hypoxia, a key microenvironmental factor for tumor development, not only stimulates angiogenesis and glycolysis for tumor expansion, but also induces cell cycle arrest and genetic instability for tumor progression. Several independent studies have shown hypoxic blockade of cell cycle progression at the G1/S transition, arising from the inactivation of S-phase-promoting cyclin E-CDK2 kinase complex. Despite these findings, the biochemical pathways leading to the cell cycle arrest remain poorly defined. We recently showed that hypoxic activates the expression of CDNK1A encoding the CDK2 inhibitor p21Cip1, through a novel HIF-1alpha-Myc pathway that involves Myc displacement from the CDNK1A promoter by the hypoxia-inducible transcription factor HIF-1alpha. In pursuit of further understanding of the hypoxic effects on cell cycle in tumor cells, here we report that hypoxia inhibits the expression of CDC25A, another cell cycle gene encoding a tyrosine phosphatase that maintains CDK2 activity. In accordance with the HIF-1alpha-Myc pathway, hypoxia requires HIF-1alpha for CDC25A repression, resulting in a selective displacement of an activating Myc from the CDC25A promoter without affecting a canonical Myc binding in the intron. Intriguingly, HIF-1alpha alone fails to recapitulate the hypoxic effect, indicating that HIF-1alpha is necessary but insufficient for the hypoxic repression. Taken together, our studies indicate that hypoxia inhibits cell cycle progression by controlling the expression of various cell cycle genes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17671423     DOI: 10.4161/cc.6.15.4515

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  28 in total

1.  Multimodal control of Cdc25A by nitrosative stress.

Authors:  Robert J Tomko; John S Lazo
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

Review 2.  Inside the hypoxic tumour: reprogramming of the DDR and radioresistance.

Authors:  Katheryn Begg; Mahvash Tavassoli
Journal:  Cell Death Discov       Date:  2020-08-18

Review 3.  HypoxamiRs and cancer: from biology to targeted therapy.

Authors:  Harriet E Gee; Cristina Ivan; George A Calin; Mircea Ivan
Journal:  Antioxid Redox Signal       Date:  2013-11-22       Impact factor: 8.401

Review 4.  MicroRNA-210: a unique and pleiotropic hypoxamir.

Authors:  Stephen Y Chan; Joseph Loscalzo
Journal:  Cell Cycle       Date:  2010-03-15       Impact factor: 4.534

5.  Cancer Stem Cells under Hypoxia as a Chemoresistance Factor in Breast and Brain.

Authors:  Spencer W Crowder; Daniel A Balikov; Yu-Shik Hwang; Hak-Joon Sung
Journal:  Curr Pathobiol Rep       Date:  2014-03

Review 6.  Is Cdc25 a druggable target?

Authors:  John S Lazo; Peter Wipf
Journal:  Anticancer Agents Med Chem       Date:  2008-12       Impact factor: 2.505

7.  Silica-based branched hollow microfibers as a biomimetic extracellular matrix for promoting tumor cell growth in vitro and in vivo.

Authors:  Penghe Qiu; Xuewei Qu; Daniel J Brackett; Megan R Lerner; Dong Li; Chuanbin Mao
Journal:  Adv Mater       Date:  2013-03-01       Impact factor: 30.849

8.  Prevention of CCAAT/enhancer-binding protein beta DNA binding by hypoxia during adipogenesis.

Authors:  Young-Kwon Park; Hyunsung Park
Journal:  J Biol Chem       Date:  2009-11-25       Impact factor: 5.157

9.  Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1alpha.

Authors:  Lei Huang; Qilin Ao; Qinghua Zhang; Xiaokui Yang; Hui Xing; Fang Li; Gang Chen; Jianfeng Zhou; Shixuan Wang; Gang Xu; Li Meng; Yunping Lu; Ding Ma
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-16       Impact factor: 4.553

10.  Hypoxia-induced alterations of G2 checkpoint regulators.

Authors:  Grete Hasvold; Christin Lund-Andersen; Malin Lando; Sebastian Patzke; Sissel Hauge; ZhenHe Suo; Heidi Lyng; Randi G Syljuåsen
Journal:  Mol Oncol       Date:  2016-01-08       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.